Correlation Between Alnylam Pharmaceuticals and CytoMed Therapeutics

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and CytoMed Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and CytoMed Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and CytoMed Therapeutics Limited, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and CytoMed Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of CytoMed Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and CytoMed Therapeutics.

Diversification Opportunities for Alnylam Pharmaceuticals and CytoMed Therapeutics

-0.37

Correlation Coefficient

Alnylam Pharmaceuticals  CytoMed Therapeutics

Very good diversification

The 3 months correlation between Alnylam and CytoMed is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and CytoMed Therapeutics Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytoMed Therapeutics and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with CytoMed Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytoMed Therapeutics has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and CytoMed Therapeutics go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and CytoMed Therapeutics

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to under-perform the CytoMed Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Alnylam Pharmaceuticals is 3.98 times less risky than CytoMed Therapeutics. The stock trades about -0.16 of its potential returns per unit of risk. The CytoMed Therapeutics Limited is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  239.00  in CytoMed Therapeutics Limited on October 10, 2024 and sell it today you would lose (10.00) from holding CytoMed Therapeutics Limited or give up 4.18% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  CytoMed Therapeutics Limited

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

CytoMed Therapeutics

Risk-Adjusted Performance

5 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in CytoMed Therapeutics Limited are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, CytoMed Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Alnylam Pharmaceuticals and CytoMed Therapeutics

The main advantage of trading using opposite Alnylam Pharmaceuticals and CytoMed Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, CytoMed Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytoMed Therapeutics will offset losses from the drop in CytoMed Therapeutics' long position.

The idea behind Alnylam Pharmaceuticals and CytoMed Therapeutics Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.